Association between antibody responses post-vaccination and severe COVID-19 outcomes in Scotland.

IF 6.9 1区 医学 Q1 IMMUNOLOGY NPJ Vaccines Pub Date : 2024-06-14 DOI:10.1038/s41541-024-00898-w
Calum Macdonald, Norah Palmateer, Andrew McAuley, Laura Lindsay, Taimoor Hasan, Safraj Shahul Hameed, Elliot Hall, Karen Jeffrey, Zoë Grange, Petros Gousias, Sally Mavin, Lisa Jarvis, J Claire Cameron, Luke Daines, Holly Tibble, Colin R Simpson, Colin McCowan, Srinivasa Vittal Katikireddi, Igor Rudan, Adeniyi Francis Fagbamigbe, Lewis Ritchie, Ben Swallow, Paul Moss, Chris Robertson, Aziz Sheikh, Josie Murray
{"title":"Association between antibody responses post-vaccination and severe COVID-19 outcomes in Scotland.","authors":"Calum Macdonald, Norah Palmateer, Andrew McAuley, Laura Lindsay, Taimoor Hasan, Safraj Shahul Hameed, Elliot Hall, Karen Jeffrey, Zoë Grange, Petros Gousias, Sally Mavin, Lisa Jarvis, J Claire Cameron, Luke Daines, Holly Tibble, Colin R Simpson, Colin McCowan, Srinivasa Vittal Katikireddi, Igor Rudan, Adeniyi Francis Fagbamigbe, Lewis Ritchie, Ben Swallow, Paul Moss, Chris Robertson, Aziz Sheikh, Josie Murray","doi":"10.1038/s41541-024-00898-w","DOIUrl":null,"url":null,"abstract":"<p><p>Several population-level studies have described individual clinical risk factors associated with suboptimal antibody responses following COVID-19 vaccination, but none have examined multimorbidity. Others have shown that suboptimal post-vaccination responses offer reduced protection to subsequent SARS-CoV-2 infection; however, the level of protection from COVID-19 hospitalisation/death remains unconfirmed. We use national Scottish datasets to investigate the association between multimorbidity and testing antibody-negative, examining the correlation between antibody levels and subsequent COVID-19 hospitalisation/death among double-vaccinated individuals. We found that individuals with multimorbidity ( ≥ five conditions) were more likely to test antibody-negative post-vaccination and 13.37 [6.05-29.53] times more likely to be hospitalised/die from COVID-19 than individuals without conditions. We also show a dose-dependent association between post-vaccination antibody levels and COVID-19 hospitalisation or death, with those with undetectable antibody levels at a significantly higher risk (HR 9.21 [95% CI 4.63-18.29]) of these serious outcomes compared to those with high antibody levels.</p>","PeriodicalId":19335,"journal":{"name":"NPJ Vaccines","volume":null,"pages":null},"PeriodicalIF":6.9000,"publicationDate":"2024-06-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11178861/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"NPJ Vaccines","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1038/s41541-024-00898-w","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"IMMUNOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Several population-level studies have described individual clinical risk factors associated with suboptimal antibody responses following COVID-19 vaccination, but none have examined multimorbidity. Others have shown that suboptimal post-vaccination responses offer reduced protection to subsequent SARS-CoV-2 infection; however, the level of protection from COVID-19 hospitalisation/death remains unconfirmed. We use national Scottish datasets to investigate the association between multimorbidity and testing antibody-negative, examining the correlation between antibody levels and subsequent COVID-19 hospitalisation/death among double-vaccinated individuals. We found that individuals with multimorbidity ( ≥ five conditions) were more likely to test antibody-negative post-vaccination and 13.37 [6.05-29.53] times more likely to be hospitalised/die from COVID-19 than individuals without conditions. We also show a dose-dependent association between post-vaccination antibody levels and COVID-19 hospitalisation or death, with those with undetectable antibody levels at a significantly higher risk (HR 9.21 [95% CI 4.63-18.29]) of these serious outcomes compared to those with high antibody levels.

Abstract Image

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
苏格兰疫苗接种后抗体反应与 COVID-19 严重后果之间的关系。
一些人群水平的研究描述了与接种 COVID-19 疫苗后抗体反应不达标有关的个别临床风险因素,但没有一项研究对多病症进行了研究。其他研究表明,接种后抗体反应不达标会降低对后续 SARS-CoV-2 感染的保护作用;但对 COVID-19 住院/死亡的保护水平仍未得到证实。我们利用苏格兰全国数据集调查了多病症与抗体阴性检测之间的关系,研究了抗体水平与接种过两次疫苗的人随后的 COVID-19 住院/死亡之间的相关性。我们发现,患有多种疾病(≥五种疾病)的人更有可能在接种疫苗后检测出抗体阴性,其因 COVID-19 住院/死亡的几率是无疾病者的 13.37 [6.05-29.53] 倍。我们还发现接种后抗体水平与 COVID-19 住院或死亡之间存在剂量依赖关系,与抗体水平高的人相比,抗体水平检测不到的人发生这些严重后果的风险明显更高(HR 9.21 [95% CI 4.63-18.29])。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
NPJ Vaccines
NPJ Vaccines Immunology and Microbiology-Immunology
CiteScore
11.90
自引率
4.30%
发文量
146
审稿时长
11 weeks
期刊介绍: Online-only and open access, npj Vaccines is dedicated to highlighting the most important scientific advances in vaccine research and development.
期刊最新文献
WHO International Standards for antibodies to HPV6 HPV11 HPV31 HPV33 HPV45 HPV52 and HPV58 Computationally designed Spike antigens induce neutralising responses against the breadth of SARS-COV-2 variants Applying causal inference and Bayesian statistics to understanding vaccine safety signals using a simulation study. Progress on the research and development of plague vaccines with a call to action. M2e nanovaccines supplemented with recombinant hemagglutinin protect chickens against heterologous HPAI H5N1 challenge.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1